Support for Small Business Innovation Research (SBIR) to Development and Testing of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44 Clinical

The summary for the Support for Small Business Innovation Research (SBIR) to Development and Testing of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44 Clinical grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Support for Small Business Innovation Research (SBIR) to Development and Testing of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44 Clinical: This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of novel and supportive technologies for the improvement of cell replacement interventions using novel methods, biomaterials and devices for type 1 diabetes (T1D) treatment.

Federal Grant Title:	Support for Small Business Innovation Research (SBIR) to Development and Testing of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44 Clinical
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Food and Nutrition Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DK-19-028
Type of Funding:	Grant
CFDA Numbers:	93.847
CFDA Descriptions:	Information not provided
Current Application Deadline:	November 3rd, 2020
Original Application Deadline:	November 3rd, 2020
Posted Date:	December 10th, 2019
Creation Date:	December 10th, 2019
Archive Date:	December 9th, 2020
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	December 10th, 2019

Applicants Eligible for this Grant: Public and State controlled institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. see the funding announcement for the eligibility details
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-19-028.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) ...; • Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Compl...; • Cooperative Centers for Experimental Hematology (CCEHs) (U54- Clinical Trial Not Allowed); • Limited Competition for the Continuation of the Caring for OutPatiEnts after Acute Kidney ...; • Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury...; • Proteomic and Metabolomic Approaches to Diagnose Diabetes and Pre-Diabetes; • Molecular Therapy Core Centers; • Pilot and Feasibility Program in Human Islet Biology
More Grants from the National Institutes of Health: • Systems Biology of Infection and Inflammation in Chronic Diseases (U19 Clinical Trial Not ...; • NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed); • Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional); • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...; • The NIDDK Disorders of Gastrointestinal Interoception Consortium (DGIC) - Clinical Researc...